Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.
dalbavancin relapse
dalbavancin resistance
lipoglycopeptide cross-resistance
walK mutation
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
29 10 2022
29 10 2022
Historique:
received:
23
02
2022
pubmed:
6
5
2022
medline:
2
11
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
A patient with end-stage renal disease received 2 doses of dalbavancin for methicillin-resistant Staphylococcus aureus (MRSA) arteriovenous fistula infection and presented 5 weeks later with infective endocarditis secondary to vancomycin, daptomycin, and dalbavancin nonsusceptible MRSA. Resistance was associated with walK and scrA mutations, reduced long-chain lipid content, and reduced membrane fluidity.
Identifiants
pubmed: 35510938
pii: 6576475
doi: 10.1093/cid/ciac341
pmc: PMC10200325
doi:
Substances chimiques
dalbavancin
808UI9MS5K
Vancomycin
6Q205EH1VU
Daptomycin
NWQ5N31VKK
Anti-Bacterial Agents
0
Teicoplanin
61036-62-2
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1641-1644Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Front Microbiol. 2016 Aug 25;7:1326
pubmed: 27610104
Clin Microbiol Infect. 2018 Apr;24(4):429.e1-429.e5
pubmed: 28782651
J Bacteriol. 2005 Apr;187(7):2357-67
pubmed: 15774879
J Clin Microbiol. 2015 Apr;53(4):1072-9
pubmed: 25631811
J Antimicrob Chemother. 2020 May 1;75(5):1182-1186
pubmed: 32016379
Front Mol Biosci. 2021 Sep 09;8:688357
pubmed: 34646861
Antimicrob Agents Chemother. 2004 Mar;48(3):940-5
pubmed: 14982787
Clin Infect Dis. 2018 Aug 16;67(5):795-798
pubmed: 29659732
PLoS Pathog. 2011 Nov;7(11):e1002359
pubmed: 22102812
Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):
pubmed: 27663982
Clin Microbiol Infect. 2021 Jun;27(6):910.e1-910.e8
pubmed: 32866650
J Bacteriol. 2007 Nov;189(22):8257-69
pubmed: 17827301
Emerg Microbes Infect. 2018 Dec 5;7(1):202
pubmed: 30514923
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
J Antimicrob Chemother. 2001 Apr;47(4):399-403
pubmed: 11266410
J Clin Pharm Ther. 2018 Feb;43(1):101-103
pubmed: 28628223
J Bacteriol. 2004 Feb;186(4):1175-81
pubmed: 14762013